Jump to search

October 2017arrow

UC Davis, CIRM host free patient-advocate event on stem cell therapies, Oct. 10

October 6, 2017

The California Institute for Regenerative Medicine (CIRM) and UC Davis are hosting a free patient advocate event about how stem cell therapies are helping patients with unmet medical needs. The event is open to the public.

September 2017arrow

UC Davis receives $8 million to expand access to stem cell clinical trials

September 28, 2017

The California Institute for Regenerative Medicine today awarded a nearly $8 million grant to University of California, Davis, stem cell researchers to launch a special clinical trials program in Sacramento to accelerate the therapeutic development and delivery of stem cell therapies in human patients.

August 2017arrow

Stem cell treatment for children with spina bifida helps dogs first

August 24, 2017

A pair of English bulldog puppies are the first patients to be successfully treated with a unique therapy — a combination of surgery and stem cells — developed at the University of California, Davis, to help preserve lower-limb function in children with spina bifida.

July 2017arrow

Life-saving Umbilical Cord Blood Collection Program extended 5 years

July 11, 2017

In a decisive move by the Governor and Legislature, the University of California Umbilical Cord Blood Collection Program (UCBCP) has been extended through 2022. The program enables mothers of newborns to donate their babies’ umbilical cord blood and have it publicly banked so it is available to anyone for lifesaving transplantations.

March 2017arrow

UC Davis joins national consortium to find regenerative treatments for dental and craniofacial tissues

March 7, 2017

UC Davis will join other California research institutions in a three-year, $12 million effort to find regenerative treatments for dental, oral and craniofacial deformities and injuries.

UC Davis licenses novel compound that helps stem cells regenerate bone

March 3, 2017

The University of California, Davis, has reached a licensing agreement with Regenerative Arthritis and Bone Medicine (RABOME) for a class of drugs developed at the university that hold potential for treating diseases associated with bone loss and inflammatory arthritis.


 

connect with us

Facebook icon  Twitter icon  YouTube icon  Pinterest icon  GooglePlus icon  LinkedIn icon